Advanced Breast Cancer, Breast Neoplasm Malignant Female
Conditions
Keywords
Breast cancer, solid tumor, CAR-T cells, PD-1 knockout, MUC1
Brief summary
This exploratory clinical study aims to assess the safety and preliminary efficacy of an immunotherapy using PD-1 knockout anti-MUC1 CAR-T cells in the treatment of advanced MUC1-positive breast cancer
Detailed description
This is a single-center, open-label, dose-escalation exploratory study investigating the safety,tolerability and preliminary efficacy of AJMUC1, PD-1 knockout CAR-T cells targeting aberrantly glycosylated MUC1, in the treatment of patients with advanced MUC1 positive breast cancer. The primary objective of this study is to evaluate the safety, tolerability, biological activity, and preliminary antitumor efficacy of AJMUC1. The study adopts a 3+3 dose escalation design to identify the maximum tolerated dose (MTD)/ maximum administered dose (MAD). Three doses are set: 3×105 CAR T cells/kg, 1×106 CAR T cells/kg and 3×106 CAR T cells/kg, with a total of 15 patients planned by the data cutoff date. Participants may receive one, two, three or more cycles of AJMUC1 infusion dependent on the adverse effects and potential clinical benefits.. This study is initiated by the investigators and approved by the Human Ethics Committee of Sun Yat-sen Memorial Hospital affiliated with Sun Yat-sen University. All patients have signed informed consent.
Interventions
DRUGAJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
Sponsors
Guangzhou Anjie Biomedical Technology Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patient age: 18-70 years (including the boundary value); 2. Pathologically diagnosed with recurrent/metastatic breast cancer (except for intracranial metastasis), who have received at least one standard treatment regimen in the past, the disease is in a stable or progressive state, and refuses to undergo subsequent chemotherapy; 3. Abnormal glycosylated MUC1 expression confirmed by immunohistochemistry in tumor tissue or puncture tissue within 12 months; 4. Expected survival period ≥ 4 months; 5. ECOG score≤2 points; 6. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; 7. Able to cooperate with tumor puncture; 8. At least one measurable lesion that meets the RECIST v1.1 criteria; 9. Female patients of childbearing age must not be breastfeeding, and serum or urine HCG test is negative within 72 hours before study enrollment. All subjects must use medically approved contraception during the study period and within 3 months after the end of the study. measures (eg, IUDs, birth control pills) for contraception; 10. Organ function and bone marrow reserve are in good condition and the following requirements must be met: (1) The absolute value of neutrophils is ≥1.5×109/L; (2) Platelet count ≥75×109/L; (3) Hemoglobin ≥9g/dl; (4) Bilirubin value \< 1.5 times the upper limit of normal (except for obstruction of the bile duct caused by tumor compression); (5) Creatinine value \< 1.5 times the upper limit of normal or creatinine clearance rate ≥ 60ml/min; (6) ALT or AST \< 2.5 times the upper limit of normal (with liver involvement \< 5 times the upper limit of normal); (7) Stable coagulation function: INR≤1.5, PTT\<1.2 times the upper limit of normal (except for tumor-related anticoagulation therapy).
Exclusion criteria
1. Have used immunosuppressive drugs or hormones within 1 week prior to enrollment; 2. Patients with moderate or more moderate pleural and ascites who need catheter drainage to relieve symptoms; 3. Human immunodeficiency virus (HIV) positive; 4. Active hepatitis B or C infection; 5. Pregnant or lactating women; 6. Past or concurrent history of other malignant tumors. Excluded: Patients with basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix who have been cured at any time prior to the study; 7. Those with central transfer; 8. Serious, uncontrollable concomitant diseases that may affect protocol compliance or interfere with the interpretation of results, or have any serious medical conditions that may affect the subject's safety (such as uncontrollable heart disease, high blood pressure, active or uncontrollable disease) infection, etc.); 9. Active autoimmune diseases (including but not limited to, systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, etc.); 10. Those with a history of organ transplantation; 11. Subjects whose last medication was less than 2 weeks before enrollment, or subjects who participated in other relevant clinical studies at the same time; 12. Those who have received gene therapy in the past; 13. Vaccination with live vaccine within 4 weeks prior to study; 14. History of myocardial infarction and severe arrhythmia within half a year; uncontrolled hypertension, coronary heart disease, stroke, liver cirrhosis, nephritis and other serious complications; 15. Those who have a history of psychotropic substance abuse and cannot quit or who have a history of mental disorders; 16. Hypersensitivity constitution, allergic to human serum albumin; 17. Hemorrhagic and thrombotic tendency: patients with clinically significant bleeding symptoms or clear bleeding tendency within 3 months before the study, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, abnormal coagulation function (PT\>16s, APTT\>43s) , TT\>21s, FIB\<2g/L), hereditary or acquired bleeding and thrombosis tendency to (such as hemophilia, coagulation disorder, thrombocytopenia, hypersplenism, etc.), are receiving thrombolytic or anticoagulation therapy, arterial/venous thrombotic events occurred within the previous 6 months, such as cerebrovascular disease (including cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism; 18. Other severe, acute, or chronic medical or psychiatric conditions that may increase the risks associated with participation in the study or may interfere with the interpretation of the study results, in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Monitoring the numbers of circulating AJMUC1 after infusion will be evaluated. | up to 3 years |
| Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v5.0 | 3 years |
| Incidence of treatment-emergent adverse events [safety and tolerability] of dose of PD-1 Knockout CAR-T cells will be assessed using CTCAE v5.0 | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival - PFS (Time from enrollment to date of first documented progression or date of death) | 3 years |
| Median CAR-T cell persistence--Will be measured by quantitative RT-PCR | 3 years |
| Response rate will be assessed according to the revised RECIST guideline iRECIST | 3 years |
| Overall Survival - OS (Measure the time from enrollment to death) | 3 years |
Other
| Measure | Time frame | Description |
|---|---|---|
| To evaluate serum cytokine changes after AJMUC1 treatment of aberrantly glycosylated MUC1 expression in advanced breast cancer | 3 years | The serum cytokine included IL-1β, IL-2R, IL-6, IL-8, TNF and IL-10 |
Countries
China
Outcome results
None listed